reduction in specific patient requirements. Demand for Recombinant Factor IX increased by 8.0 per cent in 2015-16. The increased demand was largely driven by increases in surgeries. Patient participation in company clinical trials for Extended Half Life recombinant Factor VIII and Factor IX products continues to contribute to the variability of year-to-year product growth. 17 - IX 2011-12 2015-16 Figure 18 and Figure 19 show demand for Recombinant Factor VIIa increased by 9.5 and 11.8 per cent for FEIBA compared to 2014-15. Demand for Recombinant Factor VIIa and FEIBA can change significantly from year to year as a result of the variable needs of a small number of patients. 18 - 2011-12 2015-16 19 - FEIBA, 2011-12 2015-16
reduction in specific patient requirements. Demand for Recombinant Factor IX increased by 8.0 per cent in 2015-16. The increased demand was largely driven by increases in surgeries. Patient participation in company clinical trials for Extended Half Life recombinant Factor VIII and Factor IX products continues to contribute to the variability of year-to-year product growth. 17 - IX 2011-12 2015-16 Figure 18 and Figure 19 show demand for Recombinant Factor VIIa increased by 9.5 and 11.8 per cent for FEIBA compared to 2014-15. Demand for Recombinant Factor VIIa and FEIBA can change significantly from year to year as a result of the variable needs of a small number of patients. 18 - 2011-12 2015-16 19 - FEIBA, 2011-12 2015-16